Physician profile
Daniel C Su
NPI 1508109133
$20,095.69
in general payments reported to CMS, 2019-2025
20 companies · $2,552 in 2025
The $2,552 reported for 2025 was more than what 84% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406 · 2020: $70.67 · 2021: $444 · 2022: $580 · 2023: $4,983 · 2024: $11K · 2025: $2,552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,703 · Food and Beverage: $1,586 · Travel and Lodging: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,055.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,702.67 |
| Food and Beverage | $1,586.49 |
| Travel and Lodging | $250.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,477.78 | 2022-2025 | Ozurdex |
| Regeneron Healthcare Solutions, INC. | $6,321.84 | 2019-2024 | Eylea Hd, Eylea |
| Amgen INC. | $2,329.81 | 2025 | Pavblu, Lumakras |
| Genentech USA, INC. | $2,212.48 | 2019-2025 | Vabysmo |
| Regeneron Pharmaceuticals, INC. | $940.00 | 2023 | Eylea |
| Alimera Sciences, INC. | $405.17 | 2019-2024 | Iluvien, Yutiq |
| Alcon Vision LLC | $304.47 | 2022-2025 | Constellation, Unity |
| Apellis Pharmaceuticals, INC. | $265.58 | 2022-2025 | Syfovre |
| Eyepoint US, INC. | $159.26 | 2020-2021 | |
| Allergan, INC. | $153.31 | 2019-2020 | |
| Cardinal Health 110 LLC | $150.00 | 2024 | |
| Sandoz INC. | $137.72 | 2024 | Cimerli |
| Mallinckrodt Hospital Products INC. | $92.99 | 2021 | |
| Astellas Pharma US INC | $34.45 | 2025 | Izervay |
| Biogen, INC. | $28.45 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $27.10 | 2024 | Nanoknife |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Neurotech Pharmaceuticals, INC. | $18.94 | 2025 | |
| Sun Pharmaceutical Industries INC. | $16.94 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Su listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.